The therapeutic regimen
AssigneeNovartis AG
InventorsJay Prakash Jain, Franz Joel Leong, Comelis Winnips, Marie-Christine Wolf
Life of this patent
Estimating the term…
Abstract
The present invention relates to dosing regimen of a new antimalarial drug, as monotherapy or combination therapy.
Claims12
1-6. (canceled)
A method of preventing or treating malaria, or delaying the symptoms or ameliorating the conditions associated with malaria, in a subject in need thereof, comprising administering to said subject about 200 mg to 350 mg of 2-amino-1-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone, or a pharmaceutically acceptable salt thereof, delivered daily, during 1 to 5 days.
A method of preventing or treating malaria, or delaying the symptoms or ameliorating the conditions associated with malaria, in a subject in need thereof, comprising administering to said subject about 200 mg to 1000 mg of 2-amino-1-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone, or a pharmaceutically acceptable salt thereof, in combination with a second anti-malaria drug.
A pharmaceutical combination comprising lumefantrine and a dose of about 200 mg to about 1000 mg of 2-amino-1-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.